rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2008-6rsp-290Research ArticleСтатьиArticlesАнти-В клеточная терапия синдрома и болезни ШёгренаAnti-V kletochnaya terapiya sindroma i bolezni ShegrenaVasil'evV IVasil'evV I-ЛогвиненкоО. А.LogvinenkoO A-KokosadzeN VKokosadzeN V-НасоновЕвгений ЛьвовичNasonovE L-200815022008461s№1s (2008)3439Copyright © Vasil'ev V.I., Логвиненко О.А., Kokosadze N.V., Насонов Е.Л., 20082008Vasil'ev V.I., Логвиненко О.А., Kokosadze N.V., Насонов Е.Л.Vasil'ev V.I., Logvinenko O.A., Kokosadze N.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/290References<div><p>Васильев В.И., Симонова М.В., Сафонова Т.Н. Болезнь Шёгрена. В кн. Насонова В.А., Бунчук Н.В. (ред.), Ревматические болезни, М., Медицина; 1997, 196-210.</p><p>Васильев В.И., Пробатова Н.А., Тупицын Н.Н. и др. Лимфопролифера- тивные заболевания при болезни Шёгрена. Онкогематология 2007; 3 : 16-26.</p><p>Kassan S.S., Thomas T.L., Mout- sopoulos H.M., et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med.1978, 89: 888-892.</p><p>Voulgarelis М., Dafni U.G., Isenberg D. A., et al. Malignant lymphoma in primary Sj?gren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjgren's syndrome. Arthritis Rheum.1999; 42: 1765-1772.</p><p>Васильев В.И., Пробатова Н.А., Тупицин Н.Н. и др. MALT-лимфомы при болезни Шёгрена. Тер.Арх. 2006; 1, 45-49.</p><p>Harris N.L. Lymphoid proliferations of the salivary glands. Am.J.Clin.Pathol. 1999; 111 (Suppl. 1): 94-103.</p><p>Васильев В.И. Болезнь Шёгрена: клинико-лабораторные, иммуноморфо- логические проявления и прогноз. Дис. док.мед.наук - Москва, 2007.</p><p>Поддубная И.В. Лечение индолент- ных неходжкинских лимфом. Практическая Онкология. 2004; 5(3): 203-208.</p><p>Насонов Е.Л., Соловьев С.К. Перспективы применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при воспалительных ревматических заболеваниях. Научно-практическая ревматология. 2007; 1:4-8.</p><p>Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders. Arthr.Rheum. 2003; 48(6): 1484-1491.</p><p>Cohen S.B. В-cell depletion for rheumatic disease: where are we? Med.Gen.Med. 2005 ; 7(2):1-13.</p><p>Родионова E.B., Васильев В.И., Прокопенко В.Д., Логвиненко О.А. Антигенпредставляющие клетки лимфо- гистиоцитарного инфильтрата при болезни Шёгрена. Научно-практическая ревматология. 2006; 3 : 16-20.</p><p>Harris N., Jaffe Е., Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee Meeting, Airlie House, Virginia, November, 1997. Ann.Oncol.1999; 10: 14191432.</p><p>Carbone P.P., Kaplan H.S., Musshoff K. et al. Report on the Committee on Hodgkin ’s Desease Studing Classification. Cancer Res.1971;31 : 1860-1861.</p><p>Shih W.J., Ghesani N., Hongming Z. et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of parotid gland in a patient with Sjogren's syndrome: before and after anti- CD20 antibody rituximab therapy. Clin. Nucl.Med.2002; 27: 142-143.</p><p>Somer B.G., Tsai D.E., Downs L. et.al. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthr.Rheum.2003; 49(3): 394-398.</p><p>Voulgarelis М., Giannouli S., Anagnostou D., Tzioufas A.G. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone [CHOP] for Sjogren's syndrome-associated В-cell aggressive non-Hodgkin’s lymphomas. Rheumatology [Oxford].2004; 43: 10501053.</p><p>Harner R.S.,Jockson L.W., Drabick J. J. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren’s syndrome. Rheumatology [Oxford],2004; 43 : 1309-1310.</p><p>Ramos-Casals М., Lopez-Guillermo A., Brito-Zeron P. et al. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis С virus infection. Lupus.2004; 13: 969-971.</p><p>Pijpe J., Imhoff G.W., Vissink A. et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann.Rhtum.Dis. 2005; 64:958-960.</p><p>Ring Т., Kallenbach М., Praetorius J. et al. Successful treatment of a patient with primary Sjogren's syndrome with Rituximab. Clin.Rheumatol.2006; 25 : 891-894.</p><p>Serror R., Sordet C., Guillevin L. Et al. Tolerance and efficacy of rituximab and changes in serum В cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann.Rheum.Dis. 2007; 66(3): 351-358.</p><p>Pijpe P., van Imhoff G.W., Spijkervet F.K., et al. Rituximab treatment in patients with Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005, 52 (9), 27402750.</p><p>Deyauchelle-Pensec V., Pennec Y, Morvan J. et al. Improvement of Sjogren's sendrome after two infusions of Rituximab (Anti-CD20). Arthr.Rheum.2007; 57(2) : 310317.</p><p>Cavalli F., Isaacson P.G., Gascoyne R.D., Zucca E. MALT Lymphas. Hematology. 2001; 241-258</p><p>Voulgarelis М., Giannjuli S., Tzioufas A. G., Moutsopoulos H.M. Long term remission of Sjogren’s syndrome associated aggressive В cell non-Hodgkin's lymphomas following combined В cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 2006; 65 : 1033-1037.</p><p>Васильев В.И., Соловьев С.К., Логвиненко О.А., Насонов Е.Л. Успешное применение Ритуксимаба при "катастрофическом" течении системной красной волчанки с синдромом Шёгрена. Научнопрактическая ревматология.2006; 3 : 3337.</p><p>Gottenberg J.E., Guillevin L., Lam- botte О. Et al. Tolerance and shortterm efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum.Dis.2005; 64:913-920</p></div><br /><div><p>Васильев В.И., Симонова М.В., Сафонова Т.Н. Болезнь Шёгрена. В кн. Насонова В.А., Бунчук Н.В. (ред.), Ревматические болезни, М., Медицина; 1997, 196-210.</p><p>Васильев В.И., Пробатова Н.А., Тупицын Н.Н. и др. Лимфопролифера- тивные заболевания при болезни Шёгрена. Онкогематология 2007; 3 : 16-26.</p><p>Kassan S.S., Thomas T.L., Mout- sopoulos H.M., et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med.1978, 89: 888-892.</p><p>Voulgarelis М., Dafni U.G., Isenberg D. A., et al. Malignant lymphoma in primary Sj?gren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjgren's syndrome. Arthritis Rheum.1999; 42: 1765-1772.</p><p>Васильев В.И., Пробатова Н.А., Тупицин Н.Н. и др. MALT-лимфомы при болезни Шёгрена. Тер.Арх. 2006; 1, 45-49.</p><p>Harris N.L. Lymphoid proliferations of the salivary glands. Am.J.Clin.Pathol. 1999; 111 (Suppl. 1): 94-103.</p><p>Васильев В.И. Болезнь Шёгрена: клинико-лабораторные, иммуноморфо- логические проявления и прогноз. Дис. док.мед.наук - Москва, 2007.</p><p>Поддубная И.В. Лечение индолент- ных неходжкинских лимфом. Практическая Онкология. 2004; 5(3): 203-208.</p><p>Насонов Е.Л., Соловьев С.К. Перспективы применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при воспалительных ревматических заболеваниях. Научно-практическая ревматология. 2007; 1:4-8.</p><p>Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders. Arthr.Rheum. 2003; 48(6): 1484-1491.</p><p>Cohen S.B. В-cell depletion for rheumatic disease: where are we? Med.Gen.Med. 2005 ; 7(2):1-13.</p><p>Родионова E.B., Васильев В.И., Прокопенко В.Д., Логвиненко О.А. Антигенпредставляющие клетки лимфо- гистиоцитарного инфильтрата при болезни Шёгрена. Научно-практическая ревматология. 2006; 3 : 16-20.</p><p>Harris N., Jaffe Е., Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee Meeting, Airlie House, Virginia, November, 1997. Ann.Oncol.1999; 10: 14191432.</p><p>Carbone P.P., Kaplan H.S., Musshoff K. et al. Report on the Committee on Hodgkin ’s Desease Studing Classification. Cancer Res.1971;31 : 1860-1861.</p><p>Shih W.J., Ghesani N., Hongming Z. et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of parotid gland in a patient with Sjogren's syndrome: before and after anti- CD20 antibody rituximab therapy. Clin. Nucl.Med.2002; 27: 142-143.</p><p>Somer B.G., Tsai D.E., Downs L. et.al. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthr.Rheum.2003; 49(3): 394-398.</p><p>Voulgarelis М., Giannouli S., Anagnostou D., Tzioufas A.G. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone [CHOP] for Sjogren's syndrome-associated В-cell aggressive non-Hodgkin’s lymphomas. Rheumatology [Oxford].2004; 43: 10501053.</p><p>Harner R.S.,Jockson L.W., Drabick J. J. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren’s syndrome. Rheumatology [Oxford],2004; 43 : 1309-1310.</p><p>Ramos-Casals М., Lopez-Guillermo A., Brito-Zeron P. et al. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis С virus infection. Lupus.2004; 13: 969-971.</p><p>Pijpe J., Imhoff G.W., Vissink A. et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann.Rhtum.Dis. 2005; 64:958-960.</p><p>Ring Т., Kallenbach М., Praetorius J. et al. Successful treatment of a patient with primary Sjogren's syndrome with Rituximab. Clin.Rheumatol.2006; 25 : 891-894.</p><p>Serror R., Sordet C., Guillevin L. Et al. Tolerance and efficacy of rituximab and changes in serum В cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann.Rheum.Dis. 2007; 66(3): 351-358.</p><p>Pijpe P., van Imhoff G.W., Spijkervet F.K., et al. Rituximab treatment in patients with Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005, 52 (9), 27402750.</p><p>Deyauchelle-Pensec V., Pennec Y, Morvan J. et al. Improvement of Sjogren's sendrome after two infusions of Rituximab (Anti-CD20). Arthr.Rheum.2007; 57(2) : 310317.</p><p>Cavalli F., Isaacson P.G., Gascoyne R.D., Zucca E. MALT Lymphas. Hematology. 2001; 241-258</p><p>Voulgarelis М., Giannjuli S., Tzioufas A. G., Moutsopoulos H.M. Long term remission of Sjogren’s syndrome associated aggressive В cell non-Hodgkin's lymphomas following combined В cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 2006; 65 : 1033-1037.</p><p>Васильев В.И., Соловьев С.К., Логвиненко О.А., Насонов Е.Л. Успешное применение Ритуксимаба при "катастрофическом" течении системной красной волчанки с синдромом Шёгрена. Научнопрактическая ревматология.2006; 3 : 3337.</p><p>Gottenberg J.E., Guillevin L., Lam- botte О. Et al. Tolerance and shortterm efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum.Dis.2005; 64:913-920</p></div><br />
The authors declare that there are no conflicts of interest present.